Biomarker released by the brain during injury found to stay in the bloodstream for 7 days.
Researchers at Orlando Health detected evidence of concussions in patients up to 7 days after their injury using a simple blood test, according to a new study published in JAMA Neurology. The discovery could greatly expand the window for diagnosing concussions, especially in patients who experience a delayed onset of symptoms.
“Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,” said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study. “This could provide doctors with an important tool for simply and accurately diagnosing those patients, particularly children, and making sure they are treated properly.”
It’s estimated nearly a quarter of a million children are treated in hospitals each year for concussions from playing sports, an average of nearly 700 a day. Almost all concussions in children are diagnosed only by symptoms, which are either observed, like vomiting or loss of balance, or symptoms reported by the child, like blurred vision or headaches. Neither scenario gives doctors and objective way to determine the severity of the injury.
“If patients are not diagnosed properly and treated appropriately, it could lead to long-term problems,” said Papa. Untreated, or under-treated traumatic brain injuries like concussions, can lead to prolonged bouts with headaches, dizziness, memory loss and depression.
“This test could take the guesswork out of making a diagnosis by allowing doctors to simply look for a specific biomarker in the blood.”
The biomarker Papa analyzed is known as a glial fibrillary acidic protein (GFAP). These proteins are found in glial cells, which surround neurons in the brain, and when an injury occurs, the GFAP are released. What makes them unique is that they pass the blood-brain barrier and enter the bloodstream, making them easy to detect with this particular test.
“Not only were they present in the bloodstream, we were able to detect measurable levels of GFAP up to a week after the injury,” said Papa.
Researchers analyzed nearly 600 patients for 3 years. When cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older. The blood test also indicated which patients were in need of life-saving neurosurgery. This suggests that the blood test could be used by clinicians for up to a week after injury to detect brain injury. This is important because many patients with concussion may not seek medical attention for days after injury.
The blood test could also dramatically cut down on the need for computerized tomography (CT) scans. Currently, CT scans are the most precise way to diagnose brain lesions, but are expensive and are associated with radiation exposure. “Physicians really want to minimize the amount of CTs in patients, especially children, who are a lot more sensitive to radiation and the side effects that can come with it. Fortunately, this simple blood test appears to give us nearly the same information as a CT scan.”
In fact, in a previous study published last fall, Papa and her team at Orlando Health tested both. They analyzed 152 children within 6 hours of sustaining a concussion, or mild to moderate traumatic brain injury. The results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.
“This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,” said Papa. “We have so many diagnostic blood tests for different parts of the body, like the heart, liver and kidneys, but there’s never been a reliable blood test to identify trauma in the brain. We think this test could change that,” she said.
Source: Drew Schaar – Orlando Health
Image Source: The image is credited to Orlando Health.
Original Research: Abstract for “Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury” by Linda Papa, MDCM, MSc; Gretchen M. Brophy, PharmD; Robert D. Welch, MD, MS; Lawrence M. Lewis, MD; Carolina F. Braga, BA; Ciara N. Tan, BS, MHSH; Neema J. Ameli, BS; Marco A. Lopez, AS; Crystal A. Haeussler, BS; Diego I. Mendez Giordano, BS; Salvatore Silvestri, MD; Philip Giordano, MD; Kurt D. Weber, MD; Crystal Hill-Pryor, PhD; and Dallas C. Hack, MD, MPH in JAMA Neurology. Published online March 28 2016 doi:10.1001/jamaneurol.2016.0039
Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury
Importance Glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase L1 (UCH-L1) have been widely studied and show promise for clinical usefulness in suspected traumatic brain injury (TBI) and concussion. Understanding their diagnostic accuracy over time will help translate them into clinical practice.
Objectives To evaluate the temporal profiles of GFAP and UCH-L1 in a large cohort of trauma patients seen at the emergency department and to assess their diagnostic accuracy over time, both individually and in combination, for detecting mild to moderate TBI (MMTBI), traumatic intracranial lesions on head computed tomography (CT), and neurosurgical intervention.
Design, Setting, and Participants This prospective cohort study enrolled adult trauma patients seen at a level I trauma center from March 1, 2010, to March 5, 2014. All patients underwent rigorous screening to determine whether they had experienced an MMTBI (blunt head trauma with loss of consciousness, amnesia, or disorientation and a Glasgow Coma Scale score of 9-15). Of 3025 trauma patients assessed, 1030 met eligibility criteria for enrollment, and 446 declined participation. Initial blood samples were obtained in 584 patients enrolled within 4 hours of injury. Repeated blood sampling was conducted at 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, and 180 hours after injury.
Main Outcomes and Measures Diagnosis of MMTBI, presence of traumatic intracranial lesions on head CT scan, and neurosurgical intervention.
Results A total of 1831 blood samples were drawn from 584 patients (mean [SD] age, 40  years; 62.0% [362 of 584] male) over 7 days. Both GFAP and UCH-L1 were detectible within 1 hour of injury. GFAP peaked at 20 hours after injury and slowly declined over 72 hours. UCH-L1 rose rapidly and peaked at 8 hours after injury and declined rapidly over 48 hours. Over the course of 1 week, GFAP demonstrated a diagnostic range of areas under the curve for detecting MMTBI of 0.73 (95% CI, 0.69-0.77) to 0.94 (95% CI, 0.78-1.00), and UCH-L1 demonstrated a diagnostic range of 0.30 (95% CI, 0.02-0.50) to 0.67 (95% CI, 0.53-0.81). For detecting intracranial lesions on CT, the diagnostic ranges of areas under the curve were 0.80 (95% CI, 0.67-0.92) to 0.97 (95% CI, 0.93-1.00)for GFAP and 0.31 (95% CI, 0-0.63) to 0.77 (95% CI, 0.68-0.85) for UCH-L1. For distinguishing patients with and without a neurosurgical intervention, the range for GFAP was 0.91 (95% CI, 0.79-1.00) to 1.00 (95% CI, 1.00-1.00), and the range for UCH-L1 was 0.50 (95% CI, 0-1.00) to 0.92 (95% CI, 0.83-1.00).
Conclusions and Relevance GFAP performed consistently in detecting MMTBI, CT lesions, and neurosurgical intervention across 7 days. UCH-L1 performed best in the early postinjury period.
“Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury” by Linda Papa, MDCM, MSc; Gretchen M. Brophy, PharmD; Robert D. Welch, MD, MS; Lawrence M. Lewis, MD; Carolina F. Braga, BA; Ciara N. Tan, BS, MHSH; Neema J. Ameli, BS; Marco A. Lopez, AS; Crystal A. Haeussler, BS; Diego I. Mendez Giordano, BS; Salvatore Silvestri, MD; Philip Giordano, MD; Kurt D. Weber, MD; Crystal Hill-Pryor, PhD; and Dallas C. Hack, MD, MPH in JAMA Neurology. Published online March 28 2016 doi:10.1001/jamaneurol.2016.0039